The same agent has been shown to induce death in 88% of primary AML case samples and cell lines, sparing normal lymphocytes and without substantially affecting normal bone marrow CD34-positive cells.29 Finally, it has been shown that PARP1 inhibitors may have a synergistic effect in the apoptosis of APL cells when these cells are treated with a combination of all-trans retinoic acid (ATRA) and PARP1 inhibitors.30 The gene discussed is CD34; the disease is acute myeloid leukemia.